Lantern Pharma LTRN 深 滬
已收盤 12-24 16:00:00 美东时间
3.34
-0.160
-4.57%
華盛通- 最 高3.5566
- 今 開3.50
- 成交量 2.78万股
- 最 低 3.34
- 昨 收 3.50
- 總市值 3735.59万
- 52周最高 6.118
- 市盈率 靜 --
- 換手率 0.25%
- 52周最低 2.55
- 委 比 78.54%
- 總股本 1118.44万
- 歷史最高 24.84
- 量 比 0.53
- 振 幅 6.19%
- 歷史最低 2.38
- 每 手 1
- 風險率 0.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Mersana Therapeutics (NASDAQ:MRSN) stock increased by 208.1% to $27.33...
11-13 20:06
Lantern Pharma Q3 EPS $(0.39) Beats $(0.54) Estimate
Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.54) by 27.78 percent. This is a 7.14 percent increase over losses of $(0.42) per share from the
11-13 19:03
Lantern Pharma Earnings Preview
Lantern Pharma (NASDAQ:LTRN) is preparing to release its quarterly earnings on ...
11-13 01:02
Lantern Pharma Presents Clinical Data From Ongoing Phase 1 Trial Of LP-284 At 25th Annual Lymphoma, Leukemia & Myeloma Congress
AI-advanced drug candidate achieves complete metabolic response after two cycles in patient who failed CAR-T and bispecific antibody therapies, validating LP-284's mechanism of action.A novel differentiated synthetic
10-28 20:51
快讯 | Lantern Pharma股价上涨9.5% 其抗癌药物达到早期试验目标后
Lantern Pharma Shares Rise 9.5% After Co's Cancer Drug Met Early-Stage Trial Go...
09-16 22:16
Lantern Pharma Tumor Treatment Meets Trial Endpoints
Unity Software(U.US) reported fourth-quarter financial results after the market...
09-16 20:47
Lantern Pharma's LP-184 Meets All Phase 1a Endpoints, Shows Clinical Benefit In Hard-to-Treat Cancers And Advances To Phase 2 Trials
LP-184 achieves all primary endpoints and demonstrates a favorable safety and tolerability profile positioning it for both monotherapy or synergistic combinations with PARP inhibitors and immunotherapies.Clinical benefit
09-16 20:30
快讯 | Lantern Pharma的LP-184一期1a临床试验在多种晚期实体瘤中达到所有主要终点，具有稳健的安全性特征和令人鼓舞的抗肿瘤活性
Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints ...
09-16 20:29
Lantern Pharma Completes Type C Meeting With FDA, Advancing Pediatric CNS Cancer Trial Including Atypical Teratoid Rhabdoid Tumor
Lantern Pharma Inc. (NASDAQ:LTRN), an AI-driven clinical -stage oncology company developing targeted therapies for cancer that are being advanced using its proprietary computational biology and machine learning platform,
09-03 21:47
Lantern Pharma shares are trading lower. The company reported Q2 financial results.
Lantern Pharma shares are trading lower. The company reported Q2 financial resu...
08-14 23:52
